Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Pipeline Review, H2 2016
Summary
Global Markets Direct’s, ‘Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Pipeline Review, H2 2016’, provides in depth analysis on Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted pipeline therapeutics.
The report provides comprehensive information on the Respiratory Syncytial Virus Fusion Protein (RSV F Protein), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation.
Scope
- The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - The report reviews Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics and enlists all their major and minor projects - The report assesses Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Respiratory Syncytial Virus Fusion Protein (RSV F Protein) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Fusion Protein (RSV F Protein) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Fusion Protein (RSV F Protein) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
The protein A resin market is expected to reach USD 1.9 billion by 2025 from USD 1.1 billion in 2020, at a CAGR of 11.4% during the forecast period. The protein A resin market has witnessed increasing consumption due to increased monoclonal antibody production on account of the pandemic situation worldwide.. Growth in the market can primarily...
Report Synopsis Due to the COVID-19 Pandemic, telehealth and tele-detailing (also called remoter detailing or web calls) have set forth that allow a biosimilars companies’ commercialization branch to have a wide range with less few reps. Also, the fluidity of the labor market is another new dynamic allowing for a greater...
200 pages •
By The Business Research Company
• Dec 2020
Major players in the enzymes market are Sanofi, AbbVie Inc., Alexion Pharmaceuticals Inc, Horizon Pharma, Allergan plc, Pfizer Inc., Vivus, Digestive Care, Leadiant Biosciences and Roche Holdings AG. The global enzymes market is expected to decline from $7.98 billion in 2019 to $7.81 billion in 2020 at a compound annual growth rate...
200 pages •
By The Business Research Company
• Dec 2020
Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical and Regeneron Pharmaceuticals. The global interleukin inhibitors market is expected to decline from $18.22 billion in 2019 to $17.93 billion in 2020 at a compound annual growth...
Insulin Like Growth Factor I - Pipeline Review, H2 2020
Summary
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Insulin-like growth factor 1 (IGF-1) also called somatomedin C is a protein encoded by the IGF1 gene. It stimulates glucose transport in bone-derived...
The anti-money laundering solution market was valued at US$ 1,503.99 million in 2019 and is projected to reach US$ 5,866.51 million by 2027; it is expected to grow at a CAGR of 16.2% from 2020 to 2027. Transaction monitoring is a crucial procedure and key control in anti-money laundering (AML) and countering the financing of terrorism (AML/CFT)...
The injectable drugs market is expected to register a CAGR of nearly 11.1% during the forecast period. With an upsurge in the number of chronic diseases like diabetes and cancer, the need for drug delivery systems has risen substantially in the market. From the past one era of healthcare, biologics are increasingly becoming the driving...
206 pages •
By The Business Research Company
• Dec 2020
Pegfilgrastim Biosimilars Global Market Opportunities And Strategies To 2030: COVID 19 Impact And Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global pegfilgrastim biosimilars market. Description: Where is the largest and fastest growing...
Drug Development Sector Scorecard - Thematic Research
Summary
The pharmaceutical industry is under increasing pressures with rising R&D costs, patent expiries, greater competition, and pricing challenges all eroding profit margins. Companies must invest in the right areas of drug development to...
Pharmaceutical
Biopharmaceutical
World
Pharmaceutical Exports
Biosimilar Penetration Rate
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.